TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31784746
Drug: Circulating triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating triglycerides (TG) measured via log transformation of mg/dl data
Study: 26901007
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g I/kg BW
Study: 26901007
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g I/kg BW
Study: 26901007
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g I/kg BW
Study: 17161535
Drug: Lamotrigine 400
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 400 mg
Study: 17161535
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg
Study: 17161535
Drug: Lamotrigine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (300 and 400 mg)
Study: 10445538
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium citrate (296 cc) with oral bisacodyl (10 mg)
Study: 10445538
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium citrate (296 cc) with one hypertonic phosphate enema
Study: 10445538
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium citrate (296 cc) with two hypertonic phosphate enemas
Study: 10445538
Drug: Oral bisacodyl
Normalized name: bisacodyl Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisacodyl regimen
Study: 10445538
Drug: Oral bisacodyl
Normalized name: bisacodyl Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisacodyl preparation
Study: 7847429
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone injections (0.05 mg/kg IBW for 28 days)
Study: 387417
Drug: Pirbuterol 10
Normalized name: pirbuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 10 mg plus hydroxyzine 10 mg
Study: 387417
Drug: Pirbuterol 10
Normalized name: pirbuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 10 mg plus placebo
Study: 14693576
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg FDP IV before surgery and 2.5 mM FDP as a cardioplegic additive (n = 15)
Study: 14693576
Drug: FDP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDP treatment across all regimens (n = 88; 44 FDP, 44 control)
Study: 11836046
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 625 mg (250 mg elemental calcium) three times a day (group A)
Study: 11836046
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 625 mg (250 mg elemental calcium) plus 0.625 mg/day of conjugated equine estrogen and 5 mg medrogestone acetate (group B)
Study: 10071455
Drug: Control (flomoxef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (flomoxef sodium and tobramycin without G-CSF)
Study: 2247106
Drug: A‐64077 (5‐lipoxygenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐64077 (5‐lipoxygenase inhibitor)
Study: 25770987
Drug: Heparin-bonded grafts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded grafts
Study: 17047639
Drug: Hypertriglyceridemic waist
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypertriglyceridemic waist (HTGW) defined as waist circumference (WC) > or =90 cm and triglycerides (TG) > or =2 mmol/l
Study: 7779548
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 micrograms daily as enriched yeast for 4 months)
Study: 2157450
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (30 g/day)
Study: 393519
Drug: Flutonidin (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutonidin (0.5, 1, 2 mg)
Study: 393519
Drug: Clonidine (0.0075,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.0075, 0.150, 0.300 mg)
Study: 30217337
Drug: Re-irradiation with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation with stereotactic body radiation therapy (SBRT), median BED10 of first SBRT 59.5 Gy (48-85.5 Gy), second SBRT 50.2 Gy (43.7-66.9 Gy) in training cohort; median BED10 of first SBRT 59.5 Gy (52.5-66.9 Gy), second SBRT 47.7 Gy (40.6-54.8 Gy) in validation cohort.
Study: 23147173
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg within 24 hours before contrast media exposure)
Study: 20030684
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal (at day 5)
Study: 20030684
Drug: Late steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late steroid withdrawal (at month 6)
Study: 18928685
Drug: Nebulised single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised single dose of two 12 microg Formoterol Fumarate capsules diluted in 2.5 ml of sterile saline solution.
Study: 18928685
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Albuterol (0.15 mg/kg/dose, maximum dose 2.5 mg) every twenty minutes for one hour.
Study: 11796358
Drug: Valaciclovir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir with 1 g of probenecid
Study: 11796358
Drug: Valaciclovir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir with 800 mg of cimetidine
Study: 10374166
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac eyedrops
Study: 10374166
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate eyedrops
Study: 1880232
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (specific NSAIDs and centrally acting analgesic) administered 30 minutes before RSE.
Study: 1880232
Drug: Standard drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drugs (NSAIDs and centrally acting analgesic).
Study: 6313591
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) administered intravenously at 8-hourly intervals, total daily dosage of 1500 mg/m2 for 5 days.
Study: 25280408
Drug: Hypoxia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Study: 25280408
Drug: Hypoxia after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia after 6 d of glutamine supplementation (20 g/d) and supplementation with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Study: 22320409
Drug: midazolam+fentanyl and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam+fentanyl and topical anesthesia
Study: 22320409
Drug: dexmedetomidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine and topical anesthesia
Study: 20034685
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg/d
Study: 21194594
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg/d + Atorvastatin 10 mg/d
Study: 7582165
Drug: Parenteral paramethasone
Normalized name: paramethasone
DrugBank: Paramethasone acetate (DB14657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral paramethasone (Triniol)
Study: 7582165
Drug: Other corticosteroids
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other corticosteroids (oral and parenteral challenges)
Study: 1541981
Drug: rIL‐2 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIL‐2 alone (10,000 IU/injection, escalated to 50,000 IU)
Study: 31651801
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (10 mg/kg, max 800 mg)
Study: 26137537
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (200 mg, 14 daily doses)
Study: 21204958
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg three times daily prior to meals
Study: 21204958
Drug: Glyburide 5
Normalized name: glyburide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 5 mg once daily before breakfast
Study: 18078907
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate plus atorvastatin (Lipitor)
Study: 16492394
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at concentrations of 5, 10, 20, and 40 parts per million (ppm) for 15 min
Study: 7942731
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day for 8 days
Study: 7942731
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for 8 days
Study: 3220075
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer (GP) diet supplement (230 g of GP consumed daily)
Study: 3220075
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer (GP) diet supplement
Study: 3220075
Drug: Placebo (saccharin‐sweetened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saccharin‐sweetened supplement)
Study: 27926471
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (EBRT) ≥40 Gy
Study: 27926471
Drug: Any kind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any kind of chemotherapy (CTX)
Study: 27926471
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment regimen
Study: 25469044
Drug: Boceprevir-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir-based triple therapy (PEG-IFNα2b/RBV followed by PEG-IFNα2b/RBV+Boceprevir for 32 weeks)
Study: 25469044
Drug: Boceprevir-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir-based triple therapy
Study: 23122795
Drug: Chronic subcutaneous
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic subcutaneous B-type natriuretic peptide (BNP) 10 μg/kg bid for 8 weeks
Study: 19644406
Drug: 100 mg.d(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg.d(‐1) CoQ10
Study: 18599165
Drug: IC51 vaccine
Normalized name: Japanese encephalitis vaccine IC51
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC51 vaccine
Study: 18599165
Drug: JE-VAX vaccine
Normalized name: Je-Vax Vaccine Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-VAX vaccine
Study: 7540566
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU oxytocin diluted in 10 ml 0.9% sodium chloride solution
Study: 7540566
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml plasma expander (dextran 70) into the umbilical vein
Study: 2574262
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine (20 mg salt/kg followed by 10 mg/kg every 12 h)
Study: 5762041
Drug: (-)-hyoscine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-hyoscine 0.4 mg
Study: 5762041
Drug: (-)-hyoscine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-hyoscine 0.2 mg
Study: 5762041
Drug: (-)-hyoscine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-hyoscine 0.1 mg
Study: 5762041
Drug: (-)-hyoscine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-hyoscine 0.05 mg
Study: 28687377
Drug: Whole Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Brain Radiotherapy (WBRT) - 30 Gy in ten daily fractions or 37.5 Gy in 15 daily fractions
Study: 26258842
Drug: ABA training
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABA training combined with oral bumetanide (0.5 mg twice a day)
Study: 20842417
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine and Western medicine (TCM)
Study: 20842417
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine treatment (WM)
Study: 17920550
Drug: Statins in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins in combination with existing agents for multiple sclerosis therapy
Study: 11457465
Drug: HN-11 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-11 500 (1, 10, 100, 200, and 400 mg)
Study: 11457465
Drug: HN-11 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-11 500 (400 mg)
Study: 11457465
Drug: HN-11 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN-11 500 (10 mg)
Study: 349324
Drug: Hexoprenaline sulphate
Normalized name: hexoprenaline
DrugBank: Hexoprenaline (DB08957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline sulphate (1 mg)
Study: 25275341
Drug: Enzyme combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme combination (XB)
Study: 25275341
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oils + enzyme combination (EO+XB)
Study: 22729296
Drug: Maltodextrin at
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin at 12.5% (400 ml 6 hours before and 200 ml 2 hours before)
Study: 17978033
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered after precompetition training with morphine
Study: 17978033
Drug: Morphine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administered during precompetition training
Study: 15726333
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0, 8, 16, and 32 mg per 70 kg)
Study: 15903
Drug: Intraamniotic prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraamniotic prostaglandin F2alpha (50 mg single dose)
Study: 15903
Drug: Intraamniotic prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraamniotic prostaglandin F2alpha (25 mg repeated dose)
Study: 19332204
Drug: Transradial PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transradial PCI with maximal antiplatelet therapy (aspirin and clopidogrel, 70 U/kg heparin, abciximab before first balloon inflation)
Study: 16494145
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous morphine (Group C - control group)
Study: 8445231
Drug: Oral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pulse prednisone therapy (90 mg daily for 5 days each month)
Study: 8445231
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily dose therapy with prednisone in combination with azathioprine
Study: 8445231
Drug: Oral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pulse prednisone therapy
Study: 3524066
Drug: Indomethacin, 50
Normalized name: Indomethacin, 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 50 mg t.i.d. for 6 days
Study: 24481415
Drug: Conventional stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stepwise predefined fever management using antipyretic medication and surface cooling (Control)
Study: 22751270
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment combining medical-nutritional interventions and family psychotherapy
Study: 11814498
Drug: PGE2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (2.5 mg)
Study: 7591118
Drug: Norwegian group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwegian group B meningococcal OMV vaccine (3 doses)
Study: 7591118
Drug: Norwegian group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwegian group B meningococcal OMV vaccine (2 doses)
Study: 2186023
Drug: Clonazepam treatment
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam treatment group
Study: 368045
Drug: Penfluridol (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol (once weekly)
Study: 368045
Drug: Chlorpromazine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (once daily)
Study: 31814312
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed therapy (DOT) during the continuation phase of anti-TB therapy
Study: 31814312
Drug: Body mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body mass index (BMI) change during anti-TB treatment
Study: 28418209
Drug: Acupressure band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure band at the Neiguan point (P6) for 12 hours daily for three days
Study: 26978418
Drug: ARTRA MSM
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTRA MSM (400 mg chondroitin sulfate, 500 mg glucosamine hydrochloride, 300 mg methylsulfonylmethane (MSM), and 10 mg sodium hyaluronate) taken as 2 tablets daily for one month, then 1 tablet daily
Study: 1761065
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg b.d. for 1 week
Study: 30680768
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy (AM)
Study: 25683116
Drug: larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: larazotide acetate 0.5 mg 3 times daily
Study: 24804871
Drug: Trans-resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-resveratrol (250 mg) with 20 mg piperine
Study: 24804871
Drug: Trans-resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-resveratrol (250 mg)
Study: 21519222
Drug: Palonosetron +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron + Dexamethasone (8-mg dexamethasone + 0.075-mg palonosetron)
Study: 21519222
Drug: Palonosetron alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron alone (0.075 mg palonosetron)
Study: 19242322
Drug: Unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned heparin (UFH) 500 units/hour for 7 days
Study: 14666114
Drug: L‐759274 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐759274 40 mg daily
Study: 9696260
Drug: Conventional flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional flap therapy
Study: 2759945
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, twice daily for 5 days)
Study: 785691
Drug: Defibrase (snake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrase (snake venom enzyme) administered daily for 3 weeks
Study: 28319018
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum progesterone (≥4.6 nmol/l)
Study: 26087584
Drug: Stimulant mesocarb
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant mesocarb
Study: 26087584
Drug: Nootropic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropic and anxiolytic fenibut
Study: 26087584
Drug: Tranquilizer fenazepam
Normalized name: medazepam
DrugBank: Medazepam (DB13437)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranquilizer fenazepam
Study: 24284358
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (SET) after percutaneous transluminal angioplasty (PTA)
Study: 16243460
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 0.30% retinol for 21 days
Study: 16243460
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 0.55% retinyl palmitate for 21 days
Study: 16243460
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of 10,000 IU retinyl palmitate
Study: 16243460
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of 30,000 IU retinyl palmitate
Study: 12827681
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative radiation therapy (RT) at 50 Gy in daily fractions of 2 Gy, 5 days/week for 5 weeks
Study: 12827681
Drug: Sequential postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential postoperative RT plus chemotherapy (CT) with 5-FU (450 mg/sqm/day i.v. bolus, days 1-5) and LEV (150 mg/day orally, days 1-3)
Study: 12827681
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative radiation therapy (RT) alone
Study: 12827681
Drug: Sequential postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential postoperative RT and CT
Study: 11018607
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm (nifedipine XL, prednisone, trimethoprim/sulfa, plain acetaminophen)
Study: 11018607
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (ketorolac, oxycodone, acetaminophen, prochlorperazine)
Study: 1501619
Drug: Carrot-rice based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot-rice based rehydration solution (Na 57 mmol/L)